Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2016', provides an overview of the Vertex Pharmaceuticals Incorporated's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Vertex Pharmaceuticals Incorporated, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Vertex Pharmaceuticals Incorporated - The report provides overview of Vertex Pharmaceuticals Incorporated including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Vertex Pharmaceuticals Incorporated's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Vertex Pharmaceuticals Incorporated's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Vertex Pharmaceuticals Incorporated's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vertex Pharmaceuticals Incorporated - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vertex Pharmaceuticals Incorporated's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Vertex Pharmaceuticals Incorporated Snapshot 6 Vertex Pharmaceuticals Incorporated Overview 6 Key Information 6 Key Facts 6 Vertex Pharmaceuticals Incorporated - Research and Development Overview 7 Key Therapeutic Areas 7 Vertex Pharmaceuticals Incorporated - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 15 Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Vertex Pharmaceuticals Incorporated - Unknown Stage Pipeline Products 20 Unknown Products/Combination Treatment Modalities 20 Vertex Pharmaceuticals Incorporated - Drug Profiles 21 (ivacaftor + tezacaftor) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 telaprevir 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 VX-150 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 VX-371 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 VX-210 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 VX-970 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 VX-152 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 VX-440 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 VX-803 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 VX-984 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 VE-465 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 VE-821 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 VX-241 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 VXC-486 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule to Antagonize CGRP Receptor for Migraine 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Inhibit PI3K Gamma for Undisclosed Indication 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules for Multiple Sclerosis 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 VT-12008911 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 P-1055 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Vertex Pharmaceuticals Incorporated - Pipeline Analysis 46 Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 46 Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 48 Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 49 Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 50 Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 52 Vertex Pharmaceuticals Incorporated - Dormant Projects 59 Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 60 Discontinued Pipeline Product Profiles 60 ALS-2158 60 telaprevir 60 VX-759 60 VX-983 60 Vertex Pharmaceuticals Incorporated - Company Statement 61 Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 64 Head Office 64 Other Locations & Subsidiaries 64 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables
Vertex Pharmaceuticals Incorporated, Key Information 6 Vertex Pharmaceuticals Incorporated, Key Facts 6 Vertex Pharmaceuticals Incorporated - Pipeline by Indication, 2016 8 Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2016 10 Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2016 11 Vertex Pharmaceuticals Incorporated - Combination Treatment Modalities in Pipeline, 2016 12 Vertex Pharmaceuticals Incorporated - Out-Licensed Products in Pipeline, 2016 13 Vertex Pharmaceuticals Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 Vertex Pharmaceuticals Incorporated - Phase III, 2016 15 Vertex Pharmaceuticals Incorporated - Phase II, 2016 16 Vertex Pharmaceuticals Incorporated - Phase I, 2016 17 Vertex Pharmaceuticals Incorporated - Preclinical, 2016 18 Vertex Pharmaceuticals Incorporated - Discovery, 2016 19 Vertex Pharmaceuticals Incorporated - Unknown, 2016 20 Vertex Pharmaceuticals Incorporated - Pipeline by Target, 2016 46 Vertex Pharmaceuticals Incorporated - Pipeline by Route of Administration, 2016 48 Vertex Pharmaceuticals Incorporated - Pipeline by Molecule Type, 2016 49 Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action, 2016 50 Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates, 2016 52 Vertex Pharmaceuticals Incorporated - Dormant Developmental Projects,2016 59 Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products, 2016 60 Vertex Pharmaceuticals Incorporated, Other Locations 64 Vertex Pharmaceuticals Incorporated, Subsidiaries 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
